Send the following on WhatsApp
Continue to Chat歐盟核准阿斯特捷利康 PD-L1 與 CTLA-4 抗體併用 治療晚期肝癌與肺癌 https://geneonline.news/az-nivolumab-ipilimumab-antibody/?variant=zh-cn
歐盟核准阿斯特捷利康 PD-L1 與 CTLA-4 抗體併用 治療晚期肝癌與肺癌 https://geneonline.news/az-nivolumab-ipilimumab-antibody/?variant=zh-cn